Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="896476.fig.004a" src="https://static.hindawi.com/articles/ijpro/volume-2011/896476/figures/896476.fig.004a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Galectin-3-binding protein</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="896476.fig.004b" src="https://static.hindawi.com/articles/ijpro/volume-2011/896476/figures/896476.fig.004b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b></td></tr></table></td></tr><tr class="fig-image" id="c"><td><img alt="896476.fig.004c" src="https://static.hindawi.com/articles/ijpro/volume-2011/896476/figures/896476.fig.004c.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(c) </b></td></tr></table></td></tr></table>

<table>G3BP expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated G3BP expressions found in TNBC group by LC-MS/MS and confirmed by IHC in most of the frozen TNBC tumors. (a) Normalized spectrum count of G3BP detected from 39 breast cancer tissues. (b) Immunohistochemical  staining  of G3BP in a TNBC frozen tumor (power 200x). (c) Immunohistochemical  staining of G3BP in a HER2+ frozen tumor (power 200x).</table>

International Journal of Proteomics

fig4

Figure 4

Figure 4: Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response 